Chat with John Evans
Chief Medical Officer at AstraZeneca
About John Evans
In 2021, John Evans led AstraZeneca’s pivotal pivot to biomarker-stratified trial designs in oncology, replacing broad patient cohorts with genetically defined subpopulations across eight Phase III studies, accelerating median time-to-first-patient-enrolment by 47%. His insistence on embedding real-world evidence loops into protocol development, not as an afterthought but as a co-primary endpoint, reshaped how the MHRA evaluates accelerated approvals. Raised in Sheffield and trained at St Bartholomew’s, he carries a clinician’s impatience with siloed data: his team built the first internal ‘clinical-data mesh’ linking EHRs, wearables, and central lab APIs without compromising GDPR-compliant audit trails. He doesn’t speak of AI as disruption but as delegation, freeing physicians from documentation drag so they can interpret nuance that algorithms still miss. His annual 'Medical Strategy Review' isn’t a PowerPoint deck; it’s a live-coded simulation where regulatory pathways, health economics models, and trial feasibility metrics evolve in real time against shifting NHS commissioning rules.
Why Chat with John Evans?
John Evans is one of the most iconic characters in Business & Finance. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with John Evans
Ask questions, explore ideas, and learn something new. Free with an account, and no card.
Chat with John Evans NowCall John Evans and talk out loud
You do not have to type. Call John Evans and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.
Call John Evans How calling worksConversation Starters
Not sure where to begin? Try asking John Evans:
- “How did the FLAURA2 trial redesign change AZ's approach to EGFR-mutated NSCLC?”
- “What's your stance on using UK Biobank data for adaptive trial enrichment?”
- “How do you reconcile NICE's QALY thresholds with accelerated approval for ultra-rare indications?”
- “What clinical decision support tools are you piloting with NHS Trusts this quarter?”
